ABN 53 075 582 740

BIONOMICS LIMITED

ASX half-year information – 31 December 2017

Lodged with the ASX under Listing Rule 4.2A

Contents

Results for announcement to the market

				$
Cash and cash equivalents as at 31 December 2017 from 30 June 2017	decreased by	25%	to	32,021,177
Net operating and investing cash outflows for the period	increased by	412%	to	12,308,176
Revenue from ordinary activities	increased by	1%	to	7,168,539
Loss for the half-year before income tax expense	increased by	10%	to	10,578,213
Loss from ordinary activities after tax attributable to members	decreased by	9%	to	8,846,833

Explanation of cash and cash equivalents position as at 31 December 2017:
Closing cash and cash equivalents is in line with expectations, with funds used to enable Bionomics to: submit and have accepted by the US FDA a PTSD-specific IND, activate 20 clinical trial sites across the US and have enrolment track to expectations in the Phase 2 clinical trial of BNC210 in PTSD, complete enrolment and report positive initial data in the BNC101 Phase 1 clinical trial in patients with metastatic colorectal cancer in October 2017 and continue to utilize its drug discovery platforms to identify differentiated drug candidates. The FY17 R&D Tax Incentive refund ($6.788 million) was received in January 2018.

Explanation of revenue from ordinary activities:
Revenue consists of collaboration income, royalties, sales income, rental income and interest income received as a result of ordinary activities. Government grants and assistance (including the Research and Development Tax Incentive), and other sundry forms of income are classified as other income.

Explanation of net loss from ordinary activities after tax:
The loss was in line with Directors' and Management expectations.

Dividends/distributions:
Bionomics Limited does not propose to pay any dividends for the half-year ended 31 December 2017.

NTA Backing

	Half-year	
	2017	**2016**
Net tangible asset backing per ordinary share	4.8 cents	5.3 cents

Bionomics

ABN 53 075 582 740

ASX ANNOUNCEMENT
14 February 2018

BIONOMICS' HALF-YEAR REPORT

- **Continued progress in patient enrolment into clinical trials**
  - **Enrolment into BNC210 Phase 2 trial in Post Traumatic Stress Disorder (PTSD) on track with results anticipated 2H, CY2018**
  - **BNC101 Phase 1 trial in metastatic colon cancer completed enrolment in October 2017, confirming safety and tolerability and recommended Phase 2 dose level**
- **Strong cash position to complete PTSD trial**
  - **Cash at 31 December 2017 was $32,021,177**
  - **R&D Tax Incentive of $6.788m was received in January 2018 adding to Bionomics' cash position**

Adelaide, Australia: Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its half-year report for the six months ended 31 December 2017.

Events reported in the period are supportive of Bionomics' strategy and continued progress in the development of its key drug candidates.

During the year Bionomics' lead asset BNC210, in development for the treatment of anxiety disorders, conditions with co-morbid anxiety and stress and trauma related disorders, made considerable progress towards recruiting the targeted 192 patients in the ongoing Phase 2 clinical trial in PTSD.

As foreshadowed at the FY17 full year results, over the period Bionomics expanded the evaluation of BNC210 in PTSD through a successful, PTSD focused IND submission to the US FDA and the activation of 20 clinical trial sites in the US, in addition to the 5 clinical trial sites in Australia.

A number of recent BNC210 presentations have highlighted the ongoing Phase 2 trial in PTSD patients, the positive Phase 2 trial in patients with Generalised Anxiety Disorder (GAD), the unmet clinical need in treatment of these conditions and the significant market potential of BNC210.

Whilst BNC210, Bionomics' proprietary ionX drug discovery platform and our important relationship with Merck & Co., (known as MSD outside the US and Canada) are the primary focus of the Company, in October 2017 Bionomics' reported progress in its' BNC101 Phase I clinical trial in patients with metastatic colon cancer.

Positive data from the BNC101 Phase 1 trial was reported providing confirmation of the recommended Phase 2 dose level, the safety and tolerability of BNC101 and giving indications of target engagement in patient’s tumours. These data are highly supportive of our ongoing licensing efforts initiated via a formal process in October 2017.

Outlook

Bionomics has built a globally competitive business with integrated drug discovery and development expertise to support strategic partnerships and clinical development of its drug candidates.

BNC210 Phase 2 PTSD clinical trial enrolment is ongoing and data from the clinical trial are anticipated in the second half of CY2018. Details of the trial can be found at its dedicated website https://restoreresearchstudy.com.

Bionomics has continued to work closely with MSD, enabling MSD to reach clinical trial milestones. We are also executing on other ion channel discovery programs within our core areas of expertise of cognition, depression, PTSD and pain, to further demonstrate our skills in drug discovery.

In parallel, Bionomics continues to progress potential partnership discussions and the monetisation of non-core assets.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Bionomics Ltd.
Deborah Rathjen
CEO & Managing Director
+61 8 8354 6100
drathjen@bionomics.com.au

Bionomics Ltd.
Steven Lydeamore
CFO
+61 8 8354 6100
slydeamore@bionomics.com.au

About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates targeting ion channels. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for posttraumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanised monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co.,Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

ABN 53 075 582 740

BIONOMICS LIMITED
Half-Year Report – 31 December 2017

Contents

Page

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2017 and any public announcements made by Bionomics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Your Directors present their report on the consolidated entity (the Group) consisting of Bionomics Limited (the Company) and the entities it controlled at the end of, or during, the half-year ended 31 December 2017. In order to comply with the provisions of the Corporations Act 2001, the Directors report as follows:

DIRECTORS

The names of the Directors of the Company during or since the end of the half-year:

- Dr Errol De Souza, Non-Executive Director and Chairman
- Dr Deborah Rathjen, Chief Executive Officer and Managing Director
- Mr David Wilson, Non-Executive Director
- Mr Peter Turner, Non-Executive Director
- Mr Alan Fisher, Non-Executive Director

PRINCIPAL ACTIVITIES

The principal activities of the Group during the period include the discovery and development of novel drug candidates focused on the treatment of central nervous system disorders and cancer by leveraging our proprietary platform technologies.

DIVIDENDS

The Directors' do not propose to make any recommendation for dividends for the current financial year.

REVIEW OF OPERATIONS

Cash at the end of the half-year was $32,021,177 ($42,873,656 at 30 June 2017) and net cash used in the six month period was $10,828,011, compared to net cash used of $2,338,900 for the six month period ended 31 December 2016. Cash inflows for the current period included $3,182,779 of customer receipts and Research and Development incentives, compared to $12,513,751 for the six month period ended 31 December 2016. The FY17 R&D Tax Incentive payment was of $6,788,454 was received on January 16, 2018.

Revenue for the period including other income was $7,168,539, including the R&D Tax Incentive estimate for the half-year ended 31 December 2017, compared with revenue of $7,136,513 for the period to 31 December 2016.

The operating loss after tax of the Group for the half-year ended 31 December 2017 was $8,846,833, compared to $9,696,734 for the prior comparable period ended 31 December 2016, which was in line with expectations and reflects the Company's continued investment in its research and development programs.

Major achievements in the period include:

- Expansion of the Phase 2 clinical trial of BNC210 in patients with Post Traumatic Stress Disorder (PTSD) to enrol 192 patients and bring on stream 20 clinical trial sites in the US.

To enable the expansion of the trial into the US it was necessary for Bionomics to secure acceptance of an Investigational New Drug (IND) application specifically for the use of BNC210 in the treatment of PTSD from the US Food and Drug Administration (FDA) in addition to the active BNC210 IND for the treatment of anxiety disorders. With the expansion of the trial, recruitment is on track, and top line results are anticipated in 2H, CY2018. The release of this data will be a pivotal moment in the history of Bionomics.

- Continued success in the Bionomics – Merck & Co (MSD) collaboration which was celebrated with the annual Bionomics - MSD Symposium "Frontiers in Neuroscience Research".

Bionomics and MSD have partnered for the last 5 years to present an annual Symposium covering new developments in neuroscience research. The well attended October 2017 Symposium covered topics under the theme of Feelings and Forgetting that included PTSD, sleep and Alzheimer's Disease. In addition to live streaming and webcasting, the days' talks from a stellar group of Australian and overseas experts were covered by Bioshares. The Bioshares report is available on Bionomics' website at www.bionomics.com.au/investors/analyst-coverage.

- Prosecution of drug discovery projects in our core areas of cognition, depression, pain and PTSD.

- Completion of recruitment in the Phase 1 BNC101 clinical trial in patients with metastatic colon cancer.

On 31 October 2017 initial, positive data from the BNC101 Phase 1 trial was reported. The data is highly supportive of our on-going out-licensing effort providing confirmation of the recommended Phase 2 dose level, the safety and tolerability of BNC101 and indications of target engagement in patient's tumours.

- Initiation of a formal process to partner our clinical stage oncology assets BNC101 and BNC105, which are no longer central to our strategy.

OUTLOOK

Bionomics will continue to invest in its pipeline programs, positioning them for partnering at the appropriate time, in line with its business strategy.

We anticipate significant progress in completion of recruitment in the Phase 2 clinical trial of BNC210 in patients with PTSD. Data from this trial are anticipated to be available in the second half of calendar year 2018.

In addition to supporting our collaboration with MSD to reach clinical trial milestones, we are pursuing several drug discovery programs in our core areas of cognition, pain, depression and PTSD to further demonstrate our expertise in ion channel drug discovery.

With a robust pipeline, partnerable assets and clinical progress with BNC210 Bionomics is well placed to attract both new strategic partnerships and recognition in global capital markets, an important objective for 2018.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 8.

Signed in accordance with a resolution of the directors made pursuant to section 306(3) of the *Corporations Act 2001*.

On behalf of the directors

Dated at Adelaide this 13th day of February 2018

Errol de Souza

Deborah

Errol De Souza
Chairman

Deborah Rathjen
CEO & Managing Director

Deloitte.

Deloitte Touche Tohmatsu
ABN 74 490 121 060
11 Waymouth Street
Adelaide, SA, 5000
Australia

Phone: +61 8 8407 7000
www.deloitte.com.au

12 February 2018

The Board of Directors
Bionomics Limited
31 Dalgleish Street
THEBARTON SA 5031

Dear Board Members

Bionomics Limited

In accordance with section 307C of the Corporations Act 2001, I am pleased to provide the following declaration of independence to the directors of Bionomics Limited.

As lead audit partner for the review of the financial statements of Bionomics Limited for the half-year ended 31 December 2017, I declare that to the best of my knowledge and belief, there have been no contraventions of:

(i) the auditor independence requirements of the Corporations Act 2001 in relation to the review; and

(ii) any applicable code of professional conduct in relation to the review.

Yours faithfully

Deloitte Touche Tohmatsu
DELOITTE TOUCHE TOHMATSU

Penny Woods
Partner
Chartered Accountants

BIONOMICS LIMITED
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
for the half-year ended 31 December 2017

	Note	Half-year ended 31 Dec 2017 $	31 Dec 2016 $
Continuing operations			
Revenue		2,353,473	2,505,854
Other income		4,815,066	4,630,659
Expenses			
Research and development expenses		(11,756,779)	(9,337,487)
Administration expenses		(3,871,561)	(3,791,285)
Unrealised exchange differences		(205,878)	(941,048)
Occupancy expenses		(674,881)	(1,272,053)
Compliance expenses		(370,689)	(439,489)
Finance expenses		(866,964)	(986,208)
(Loss) before tax		(10,578,213)	(9,631,057)
Income tax benefit/(expense)	**8**	1,731,380	(65,677)
(Loss) after tax		(8,846,833)	(9,696,734)
Other comprehensive income, net of income tax			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translating foreign operations		(634,778)	517,202
Total comprehensive loss for the year		(9,481,611)	(9,179,532)
Loss attributable to:			
Owners of the Company		(9,481,611)	(9,179,532)
Loss per share from continuing operations			
		Cents	**Cents**
Basic loss per share	**4**	(1.8)	(2.0)
Diluted loss per share	**4**	(1.8)	(2.0)

The above condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

BIONOMICS LIMITED
Condensed Consolidated Statement of Financial Position
as at 31 December 2017

	Note	31 Dec 2017 $	30 June 2017 $
CURRENT ASSETS			
Cash and cash equivalents		32,021,177	42,873,656
Trade and other receivables		998,421	1,354,809
Other financial assets		550,000	550,000
Inventories		440,397	425,742
Research and development incentives receivable		11,802,908	8,537,919
Other assets		460,236	736,295
TOTAL CURRENT ASSETS		46,273,139	54,478,421
NON-CURRENT ASSETS			
Property, plant and equipment		2,762,946	2,617,675
Goodwill		12,183,757	12,264,122
Other intangible assets		13,510,977	14,330,844
Other financial assets		384,000	384,000
TOTAL NON-CURRENT ASSETS		28,841,680	29,596,641
TOTAL ASSETS		75,114,819	84,075,062
CURRENT LIABILITIES			
Trade and other payables		3,955,144	3,672,573
Borrowings	**9**	1,888,054	8,495,873
Provisions		1,493,657	1,594,410
Other financial liabilities		63,505	106,441
Other liabilities		96,448	19,509
TOTAL CURRENT LIABILITIES		7,496,808	13,888,806
NON-CURRENT LIABILITIES			
Other payables		353,466	341,703
Borrowings	**9**	18,238,231	10,013,645
Provisions		69,195	47,545
Deferred tax liabilities		2,955,527	4,771,162
Contingent consideration		14,492,057	14,558,628
TOTAL NON-CURRENT LIABILITIES		36,108,476	29,732,683
TOTAL LIABILITIES		43,605,284	43,621,489
NET ASSETS		31,509,535	40,453,573
EQUITY			
Issued capital		134,819,767	134,536,428
Reserves		13,732,333	14,122,877
Accumulated losses		(117,042,565)	(108,195,732)
Equity attributable to owners of the Company		31,509,535	40,453,573

The above condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

BIONOMICS LIMITED
Condensed Consolidated Statement of Changes in Equity
for the half-year ended 31 December 2017

Consolidated	Capital	Foreign currency translation reserve	Share-based payments reserve	Accumulated losses	Total
	$	$	$	$	$
Balance at 1 July 2016	134,392,813	5,174,632	6,041,406	(101,446,117)	44,162,734
Loss for the period				(9,696,734)	(9,696,734)
Exchange differences on translation of foreign operations	-	517,202	-	-	517,202
Total comprehensive income for the period	-	517,202	-	(9,696,734)	(9,179,532)
Recognition of Share-based payments	-	-	301,689		301,689
Issue of ordinary shares & warrants, net of transaction costs	-	-	2,507,280	-	2,507,280
Issue of ordinary shares under Employee Share Option Plan (note 3)	124,397	-	-	-	124,397
Balance at 31 December 2016	134,517,210	5,691,834	8,850,375	(111,142,851)	37,916,568
Balance at 1 July 2017	**134,536,428**	**5,060,539**	**9,052,338**	**(108,195,732)**	**40,453,573**
Loss for the period				(8,846,833)	(8,846,833)
Exchange differences on translation of foreign operations	-	(634,778)	-	-	(634,778)
Total comprehensive income for the period	-	(634,778)	-	(8,846,833)	(9,481,611)
Recognition of Share-based payments	-	-	254,234		254,234
Issue of ordinary shares under Employee Share Option Plan (note 3)	283,339	-	-	-	283,339
Balance at 31 December 2017	134,819,767	4,425,761	9,306,572	(117,042,565)	31,509,535

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes

BIONOMICS LIMITED
Condensed Consolidated Statement of Cash Flows
for the half-year ended 31 December 2017

	Half-year ended	
	31 December 2017	31 December 2016
	$	$
Cash flows from operating activities		
Research and development incentives received	946,801	9,222,092
Receipts from customers	2,235,978	3,291,659
Payments to suppliers and employees	(14,751,280)	(14,560,163)
Interest paid	(866,964)	(977,636)
Net cash (used in) operating activities	**(12,435,465)**	**(3,024,048)**
Cash flows from investing activities		
Interest received	127,289	656,004
Payments for purchases of property, plant and equipment	-	(37,183)
Net cash generated by investing activities	**127,289**	**618,821**
Cash flows from financing activities		
Net proceeds from share issues	283,339	124,397
Proceeds from borrowings	1,847,106	62,279
Repayment of borrowings	(650,280)	(120,349)
Net cash generated by financing activities	**1,480,165**	**66,327**
Net (decrease) in cash and cash equivalents	**(10,828,011)**	**(2,338,900)**
Cash and cash equivalents at the beginning of the half-year	**42,873,656**	**45,450,382**
Effects of exchange rate changes on the balance of cash held in foreign currencies	(24,468)	10,806
Cash and cash equivalents at the end of the half-year	**32,021,177**	**43,122,288**

The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTE 1: Summary of significant accounting policies

Statement of compliance

The half-year financial report is a general purpose financial report prepared in accordance with the *Corporations Act 2001* and AASB 134 'Interim Financial Reporting'. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'. The half-year report does not include notes of the type normally included in an annual financial report and shall be read in conjunction with the most recent annual financial report and any public announcements made by Bionomics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Basis of preparation

The condensed consolidated financial statements have been prepared on the basis of historical cost, except for the revaluation of certain non-current assets and financial instruments. Cost is based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars, unless otherwise noted.

The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in the Company's 2017 annual financial report for the financial year ended 30 June 2017 except for the impact of the Standards and Interpretations described below. These accounting policies are consistent with Australian Accounting Standards (AAS) and with International Financial Reporting Standards (IFRS).

Amendments to Accounting Standards that are mandatorily effective for the current reporting period

The Group has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to their operations and effective for the current reporting period. The adoption of these new and revised Standards and Interpretations has resulted in no significant changes to the consolidated entity's accounting policies.

NOTE 2: Segment information

Information reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance focuses on the nature of work processes performed. The Group's reportable segments under AASB 8 (IFRS 8) are:

- Drug discovery and development is the discovery, development and commercialisation of compounds to match a target product profile; and
- Contract services is the provision of scientific services on a fee for service basis to both external and internal customers.

Information regarding these segments is presented below.

a) Segment Revenues and Results

The following is an analysis of the Group's revenue and results by reportable operating segment for the periods under review:

	Segment revenue Half-year ended		Segment result Half-year ended	
	31 Dec 2017	31 Dec 2016	31 Dec 2017	31 Dec 2016
	$	$	$	$
Drug discovery and development	1,514,262	2,212,233	(6,446,570)	(5,287,262)
Contract services	3,325,537	3,600,803	(335,226)	241,059
	4,838,799	5,813,036	(6,781,796)	(5,046,203)
Less:				
Intercompany revenue included in				
Contract services	(2,330,257)	(3,389,642)	-	-
Corporate	(155,069)	82,460	(155,069)	82,460
	2,353,473	2,505,854	(6,936,865)	(4,963,743)
Interest income			275,518	645,599
Corporate financing expenses			(866,964)	(975,811)
Corporate administration expenses			(3,049,902)	(4,337,102)
Loss before income tax (continuing operations)			(10,578,213)	(9,631,057)

Revenue reported above for Contract services includes intersegment sales. There were no intersegment sales for the other reportable segment.

Segment result represents the profit/(loss) for each segment without allocation of central administration expenses and investment and other revenue.

Segment Assets

The following is an analysis of the Group's assets by reportable operating segment:

ASSETS	31 Dec 2017	30 June 2017
	$	$
Drug discovery and development	42,282,379	42,279,000
Contract services	5,618,999	5,760,733
	47,901,378	48,039,733
Corporate	27,213,441	36,035,329
Total assets	75,114,819	84,075,062

NOTE 3: Equity securities issued

	Half-year		Half-year	
	2017 Number of shares	2016 Number of shares	2017 $	2016 $
Ordinary shares				
Balance at the beginning of the half-year	481,456,441	480,986,821	134,536,428	134,392,813
Share issue - Employee Share Option Plan option exercise	922,500	420,000	283,339	124,397
Placements (net of warrants)[1]				
Share issue - Employee Share Plan Loan Agreements	-	37,500	-	-
Balance at the end of the half-year	482,378,941	481,444,321	134,819,767	134,517,210
Treasury Stock				
Balance at the beginning of the half-year	38,125	75,625	-	-
Share issue - Employee Share Plan Loan Agreements	-	(37,500)	-	-
Balance at the end of the half-year	38,125	38,125	-	-
Total Issued Capital	**482,417,066**	**481,482,446**	**134,819,767**	**134,517,210**

NOTE 4: (Loss) per share

	Half-year	
	2017	2016
Basic loss per share	($0.018) (1.8 cents)	($0.020) (2.0 cents)
Diluted loss per share	($0.018) (1.8 cents)	($0.020) (2.0 cents)

	Half-year	
Weighted average number of shares used as the denominator	2017 Number	2016 Number
Weighted average number of ordinary shares used as the denominator in calculating basic loss per share	481,970,700	481,218,184

NOTE 5: Change in accounting estimates

There has been no change in the basis of accounting estimates since the last annual reporting date.

NOTE 6: Contingencies and commitments

There has been no change in contingent liabilities and commitments since the last annual reporting date.

NOTE 7: Key Management Personnel

Remuneration arrangements of key management personnel are disclosed in the annual financial report.

NOTE 8: Taxation

Included in income tax benefit is $1,680,130 relating to the effect of the recent change to the United states taxation rates.

NOTE 9: Borrowings

In August 2017, the Company refinanced it's USD borrowings from Principal and Interest to Interest only, with Principal and Interest payments commencing in November 2018.

NOTE 10: Subsequent events

No matter or circumstance has arisen since 31 December 2017 that has significantly affected or may affect the consolidated entity's operations, the results of those operations or the state of affairs in future financial years.

The Directors declare that:

(a) in the Directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and

(b) in the Directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the consolidated entity.

Signed in accordance with a resolution of the Directors made pursuant to section 303(5) of the *Corporations Act 2001*.

On behalf of the Directors

Errol De Souza	**Deborah Rathjen**
Chairman	**CEO & Managing Director**

Adelaide, 13 February 2018

Deloitte Touche Tohmatsu
ABN 74 490 121 060
11 Waymouth Street
Adelaide, SA, 5000
Australia

Phone: +61 8 8407 7000
www.deloitte.com.au

Independent Auditor's Review Report to the members of Bionomics Limited

We have reviewed the accompanying half-year financial report of Bionomics Limited, which comprises the condensed consolidated statement of financial position as at 31 December 2017, and the condensed consolidated statement of comprehensive income, the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information and, the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the end of the half-year or from time to time during the half-year as set out on pages 9 to 16.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Bionomics Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Independence Declaration

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Bionomics Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.

Deloitte.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Bionomics Limited is not in accordance with the *Corporations Act 2001*, including:

(a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and of its performance for the half-year ended on that date; and

(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Deloitte Touche Tohmatsu

DELOITTE TOUCHE TOHMATSU

P Woods

Penny Woods
Partner
Chartered Accountants
Adelaide, 13 February 2018